Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis
Latest Information Update: 31 Oct 2023
At a glance
- Drugs Terlipressin (Primary)
- Indications Ascites
- Focus Adverse reactions; Pharmacokinetics
- Sponsors BioVie
- 26 Oct 2023 According to a BioVie media release, safety data from this study will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2023, taking place from November 10-14, 2023 in Boston, MA.
- 23 Jun 2022 Results presented in a BioVie Media Release.
- 25 Apr 2019 Status changed from active, no longer recruiting to completed.